Issue Date: October 23, 2006
Serono Bolsters New Drug Pipeline
Serono has licensed a late-stage drug for cognitive disorders from Italian R&D firm Newron Pharmaceuticals. Serono will pay Newron up to $200 million in up-front payments and milestones for access to safinamide, an α-aminoamide derivative that is currently in Phase III trials for Parkinson's disease. The Swiss biotech firm will also fund all future development and marketing costs for the small-molecule drug. Newron retains the right to copromote the drug in Italy and Spain.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society